Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Intravitreal Aflibercept Injection

Intravitreal Aflibercept Injection

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Intravitreal Aflibercept Injection

13 trials tracked of Intravitreal Aflibercept Injection: 6 in phase 3 or 4 and 1 with published results. The most-cited published study has 147 citations.

13Trials tracked
6Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 3 Phase 3 3 Phase 2 6 Other / NA 1
  1. Phase 3 Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) Completed · 147 cited
  2. Phase 4 EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection Completed
  3. Phase 4 Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe Completed
  4. Phase 4 Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) Completed
  5. Phase 3 Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO) Completed
  6. Phase 3 Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema Completed
Show 7 more trials
  1. Phase 2 Aflibercept Injection for Proliferative Diabetic Retinopathy Completed
  2. Phase 2 The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Completed
  3. Phase 2 IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD Completed
  4. Phase 2 Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema Completed
  5. Phase 2 Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection Completed
  6. Phase 2 DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact Completed
  7. N/A Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.